RNS Number: 8297G MaxCyte, Inc. 03 October 2024



MaxCyte, Inc.

("MaxCyte" or the "Company")

Exercise of options and PDMR dealing

ROCKVILLE, MD, October 3, 2024MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that between 1 October 2024 and 2 October 2024, as per a filing lodged with the U.S. Securities and Exchange Commission, Stanley Erck, aNon-Executive Director of the Company, exercised options over 47,689 shares of common stock of 0.01 of the Company ("Common Stock") ("Exercise") in aggregate. The 47,689 new shares of Common Stock were issued pursuant to the Company's existing its block admission facility and were sold by Stanley Erck at a price range between 3.625 and 3.880 per Common Stock ("Sale"). The sold shares represent approximately 7.94% of Stanley Erck's total equity and option holdings in the Company's stock capital, respectively.

Following the Exercise and Sale, Stanley Erck holds 247,751 shares of Common Stock representing 0.2% of the issued stock capital of the Company. Following the Exercise, Stanley Erck holds a further 324,190 options over Common Stock and 21,367 restricted stock units.

The sales and option exercises were effected pursuant to a Rule 10b5-1 trading plan adopted by Stanley Erck on 12 March 2024 relating solely to the sale of shares acquired from exercise of options that expire on 11 November 2024.

MaxCyte Contacts:

US IR Adviser

Gilmartin Group+1 415-937-5400David Deuchler, CFAir@maxcyte.com

Nominated Adviser and Joint

Corporate Broker +44 (0) 20 7886 2500 Panmure Liberum

Emma Earl / Freddy Crossley Corporate Broking Rupert Dearden

UK IR Adviser +44 (0) 203 709 5700

ICR Consilium <u>maxcyte@consilium-comms.com</u>

Mary-Jane Elliott Chris Welsh

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow Electroporation® technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™, GTx™ and VLx ™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. By providing our partners with the right technology platform, as well as scientific, technical and regulatory support, we aim to guide them on their journey to transform human health. Learn more at maxcyte.com and follow us on X (formerly Twitter) and LinkedIn.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

_				
a)	Name	Stanley Erck		
2	Reason for the notification			
a)	Position/status	Non-Executive Director		
b)	Initial notification /Amendment	Initial notification		
3	Details of the issuer, emission auctioneer or auction monitor	allowance market participant, auction platform,		
a)	Name	MaxCyte, Inc.		
b)	LEI	54930053YHXULRFCU991		
4		ection to be repeated for (i) each type of instrument; (ii) each date; and (iv) each place where transactions have		
4 a)	each type of transaction; (iii) e			
	each type of transaction; (iii) e been conducted Description of the financial instrument, type of	each date; and (iv) each place where transactions have		
	each type of transaction; (iii) ebeen conducted Description of the financial instrument, type of instrument	Common Stock of 0.01 each		
a)	each type of transaction; (iii) e been conducted Description of the financial instrument, type of instrument Identification code	Common Stock of 0.01 each US57777K1060		
a) b)	each type of transaction; (iii) estimates been conducted Description of the financial instrument, type of instrument Identification code Nature of the transaction	Common Stock of 0.01 each US57777K1060 Exercise of Options over common stock Exercise Price(s) Volume(s)		
a) b)	each type of transaction; (iii) estimates been conducted Description of the financial instrument, type of instrument Identification code Nature of the transaction Price(s) and volume(s)	Common Stock of 0.01 each US57777K1060 Exercise of Options over common stock Exercise Price(s) Volume(s)		
a) b)	each type of transaction; (iii) estimated Description of the financial instrument, type of instrument Identification code Nature of the transaction Price(s) and volume(s)	Common Stock of 0.01 each US57777K1060 Exercise of Options over common stock Exercise Price(s) Volume(s) 0.040 26,082		
a) b)	each type of transaction; (iii) estimated Description of the financial instrument, type of instrument Identification code Nature of the transaction Price(s) and volume(s) Aggregated information - Aggregated volume	Common Stock of 0.01 each US57777K1060 Exercise of Options over common stock Exercise Price(s) Volume(s) 0.040 26,082		

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Stanley Erck	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	MaxCyte, Inc.	

b)	LEI	54930053YHXULRFCU991	54930053YHXULRFCU991		
4	Details of the transaction(s): se	ection to be repeated for (i) each type of instrument; (ii)			
	1	ach date; and (iv) each place where transactions have			
	been conducted				
a)	Description of the financial	Common Stock of 0.01 each			
	instrument, type of instrument				
	Identification code	US57777K1060			
b)	Nature of the transaction	Sale of common stock			
,			Sale of common stock		
c)	Price(s) and volume(s)				
٠,	Trice(s) and volume(s)	Exercise Price(s)	Volume(s)		
		3.6900	200		
		3.6950	1301		
		3.7000	200		
		3.7050 3.7100	1600		
		3.7150	900		
		3.7200	466		
		3.7300	1001		
		3.7350	1666		
		3.7400 3.7450	200 800		
		3.7500	349		
		3.7550	975		
		3.7650	2700		
		3.7700	700		
		3.7750 3.7800	1700 104		
		3.7850	1000		
		3.7950	1200		
		3.8000	200		
		3.8050	200		
		3.8150 3.8200	1600 200		
		3.8250	700		
		3.8300	607		
		3.8350	300		
		3.8400	200		
		3.8450 3.8500	1500 300		
		3.8600	600		
		3.8650	713		
		3.8700	1000		
		3.8750 3.8800	100 500		
		5.5500			
d)	Aggregated information				
	- Aggregated volume	26,082			
		,,,,,			
	- Price	3.7784			
e)	Date of the transaction	1 October 2024			
t/	Place of the transaction	LIC Stock Eyebongo North	lag		
f)	Frace of the transaction	US Stock Exchange, Nasd	ıay		

a)	Name	Stanley Erck			
2	Reason for the notification				
a)	Position/status	Non-Executive Director			
b)	Initial notification /Amendment	Initial notification			
3	Details of the issuer, emission al auctioneer or auction monitor	issuer, emission allowance market participant, auction platform, auction monitor			
a)	Name	MaxCyte, Inc.			
b)	LEI	54930053YHXULRFCU991			
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted				
a)	Description of the financial instrument, type of instrument	Common Stock of 0.01 each			
	Identification code	US57777K1060			
b)	Nature of the transaction	Exercise of Options over common stock			
c)	Price(s) and volume(s)	Exercise Price(s) Volume(s) 0.040 21,607			
d)	Aggregated information				
	- Aggregated volume	21,607			
	- Price	0.040			
e)	Date of the transaction	2 October 2024			
f)	Place of the transaction	US Stock Exchange, Nasdaq			
1	Details of the person discharging managerial responsibilities / person closely associated				
a)	Name	Stanley Erck			
2	Reason for the notification				
a)	Position/status	Non-Executive Director			
b)	Initial notification /Amendment	Initial notification			
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor				
a)	Name	MaxCyte, Inc.			
b)	LEI	54930053YHXULRFCU991			

4		of the transaction(s): section to be repeated for (i) each type of instrument; (ii) be of transaction; (iii) each date; and (iv) each place where transactions have inducted		
a)	Description of the financial instrument, type of instrument	Common Stock of 0.01 each		
	Identification code	US57777K1060		
b)	Nature of the transaction	Sale of common stock		
c)	Price(s) and volume(s)	Exercise Price(s) 3.6250 3.6300 3.6350	Volume(s) 400 200 109	
		3.6400 3.6450 3.6500 3.6550	300 50 13 50	
		3.6600 3.6650 3.6700 3.6750	200 200 400 305	
		3.6800 3.6850 3.6900	1078 525 1700	
		3.7000 3.7100 3.7150 3.7200	1037 240 1040 9400	
		3.7210 3.7250 3.7400 3.7500 3.7650	900 251 467 142 100	
d)	Aggregated information	3.7700	2500	
-	- Aggregated volume	21,607		
	- Price	3.7131		
e)	Date of the transaction	2 October 2024		
f)	Place of the transaction	US Stock Exchange, Nasdaq		

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.